导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.03% | 1486/4773 |
| 近一周 | -1.58% | 2322/5465 |
| 近一月 | -3.57% | 2639/5421 |
| 近一季 | -9.93% | 3671/5231 |
| 近半年 | -3.25% | 2437/4920 |
| 近一年 | 8.27% | 1352/4394 |
| 近两年 | 62.09% | 1191/2954 |
| 近三年 | 38.34% | 805/2253 |
| 成立以来 | 149.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.98% 1396/4961 |
20.75% 1205/5312 |
- - |
- - |
| 2025 | 30.44% 1320/4813 |
3.03% 1214/3635 |
1.99% 1964/4076 |
23.90% 1507/4524 |
0.19% 2142/4813 |
| 2024 | 3.81% 1907/3463 |
0.71% 938/2808 |
-5.63% 1763/3014 |
12.13% 2412/3129 |
-2.59% 2142/3463 |
| 2023 | -0.37% 449/2656 |
8.91% 437/2280 |
-3.97% 985/2385 |
-2.92% 791/2515 |
-1.88% 384/2655 |
| 2022 | -17.56% 605/2207 |
-11.91% 554/1919 |
2.63% 1279/2016 |
-9.19% 255/2113 |
0.41% 1497/2208 |
| 2021 | 19.45% 193/1822 |
2.54% 217/1255 |
10.65% 444/1330 |
3.75% 397/1466 |
1.47% 923/1822 |
| 2020 | 32.90% 471/1250 |
-1.38% 216/1028 |
21.23% 241/1067 |
7.25% 796/1164 |
3.64% 897/1184 |
| 2019 | 30.51% 483/1092 |
23.75% 544/739 |
-7.19% 543/788 |
4.78% 181/850 |
8.44% 316/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 安信中证500指数增强A VS. 长安沪深300非周期A(740101) |